Results 51 to 60 of about 10,401 (200)

Dupilumab Beyond the Airway: Decreased Morbidity in a Real‐World Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Post hoc analyses of clinical trials have characterized dupilumab's adverse effects, yet the real‐world impact in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma is not well described. This study aims to characterize the risks of lymphoma, cardiovascular events, eosinophilia, joint pain, inflammatory arthritis, and ...
Emma J. Anisman, Spencer Short, Emma Tam, Benjamin F. Bitner, Abdulghafoor Alani, Marc Rosen, Mindy Rabinowitz, Damaris Pena Evertz, Elina Toskala, Gurston G. Nyquist   +9 more
wiley   +1 more source

Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? [PDF]

, 2014
The authors acknowledge the medical writing assistance received from Sam Yarwood, PhD, of Complete HealthVizion, in the form of literature searches and preparation and revision of the draft manuscript.Peer reviewedPublisher ...
Fromer, Leonard, Kaplan, Alan, Price, David, Román-Rodríguez, Miguel, van der Molen, Thys   +4 more
core   +12 more sources

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Allergy, Asthma & Clinical Immunology
Background Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with ...
Kenneth R. Chapman, Kathryn Cogger, Erin Arthurs, Callahan LaForty, Shane Golden, Bradley Millson, Koyo Usuba, Christopher Licskai   +7 more
doaj   +1 more source

The clinical question of mepolizumab in the long-term treatment of idiopathic chronic eosinophilic pneumonia; how long should we use mepolizumab?

Respiratory Medicine Case Reports
The efficacy of mepolizumab as an alternative to glucocorticoids for treating idiopathic chronic eosinophilic pneumonia (ICEP) has been reported. However, various questions remain unanswered, such as the most appropriate dose and dosage interval of ...
Masamitsu Hamakawa, Machiko Arita, Hiroshi Takahashi, Akihiko Amano, Nobuyoshi Hamao, Ayaka Tanaka, Akihiro Ito, Tadashi Ishida   +7 more
doaj   +1 more source

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma

Allergology International, 2017
Background: The MENSA trial assessed the efficacy and safety of mepolizumab in patients with severe eosinophilic asthma. This report describes the efficacy and safety of mepolizumab in Japanese patients from MENSA.
Terufumi Shimoda, Hiroshi Odajima, Arisa Okamasa, Minako Kawase, Masaki Komatsubara, Bhabita Mayer, Steven Yancey, Hector Ortega   +7 more
doaj   +1 more source

The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective The phase 3 MANDARA study demonstrated noninferiority of benralizumab versus mepolizumab for remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). More benralizumab‐treated patients achieved complete withdrawal of oral glucocorticoids (OGCs).
Parameswaran K. Nair, Bernhard Hellmich, Arnaud Bourdin, David R. W. Jayne, Florence Roufosse, Nader Khalidi, Lena Börjesson Sjö, Ying Fan, Christopher McCrae, Sofia Necander, Eva Rodríguez‐Suárez, Anat Shavit, Claire Walton, Peter A. Merkel, Michael E. Wechsler   +14 more
wiley   +1 more source

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Annals of Medicine
Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult ...
Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero   +6 more
doaj   +1 more source

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation

Фармакоэкономика, 2020
Objective – to conduct a pharmacoeconomic analysis of using omalizumab, mepolizumab and reslizumab in the treatment of patients with uncontrolled moderate and severe atopic asthma in the healthcare setting of the Russian Federation.Materials and Methods.
S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev   +2 more
doaj   +1 more source

Precision Medicine in Targeted Therapies for Severe Asthma:Is There Any Place for "omics" Technology? [PDF]

, 2018
According to the current guidelines, severe asthma still represents a controversial topic in terms of definition and management. The introduction of novel biological therapies as a treatment option for severe asthmatic patients paved the way to a ...
Bertolini, Francesca, Caminati, Marco, Facciolongo, Nicola, Galeone, Carla, Menzella, Francesco, Ruggiero, Patrizia, Scelfo, Chiara   +6 more
core   +2 more sources

Prediction of Relapse and Glucocorticoid Dependence in Eosinophilic Granulomatosis with Polyangiitis: Findings from a Large European Cohort

Arthritis &Rheumatology, Accepted Article.
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis characterized by eosinophilia, asthma, and ear, nose, throat (ENT) involvement. Although glucocorticoids (GCs) are effective in controlling symptoms, relapses and GC dependence are common.
Matthias Papo, Pauline Martinot, Renato A. Sinico, Vítor Silvestre‐Teixeira, Nils Venhoff, Maria‐Letizia Urban, Michele Iudici, Juliane Mahrhold, Francesco Locatelli, Giulia Cassone, Franco Schiavon, Benjamin Seeliger, Thomas Neumann, Claudia Feder, Matthieu Groh, Chiara Marvisi, Maxime Samson, Thomas Barba, David Jayne, Arianna Troilo, Jens Thiel, Bernhard Hellmich, Sara Monti, Carlomaurizio Montecucco, Carlo Salvarani, Jean‐Emmanuel Kahn, Bernard Bonnotte, Cécile‐Audrey Durel, Xavier Puéchal, Luc Mouthon, Loïc Guillevin, Giacomo Emmi, Augusto Vaglio, Raphaël Porcher, Benjamin Terrier, The French Vasculitis Study Group and the EGPA European Study Group   +35 more
wiley   +1 more source